Immunomodulatory drugs increase endothelial tissue factor expression in vitro

Thrombosis Research

Volumn 127, Issue 3, 2011, Pages 264-271

  Valsami, Serena ^a   Ruf, Wolfram ^b   Leikauf, Maria Sybille ^a   Madon, Jerzy ^a   Kaech, Andres ^c   Asmis, Lars M ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DALTEPARIN; LENALIDOMIDE; MESSENGER RNA; THALIDOMIDE; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN DETECTION; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ELECTRON MICROSCOPY; ENDOTHELIAL MICROPARTICLE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; UMBILICAL VEIN ENDOTHELIAL CELL;

CELL LINE; ENDOTHELIAL CELLS; HUMANS; IMMUNOLOGIC FACTORS; RNA, MESSENGER; THALIDOMIDE; THROMBOPLASTIN; UMBILICAL VEINS; UP-REGULATION;

EID: 79951943894     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2010.11.018     Document Type: Article

References (30)

1. Chanan-Khan AA, Cheson BD. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 2008;26:1544-52.
2. Kumar S, Rajkumar SV. Thalidomide and lenalidomide in the treatment of multiple myeloma. Eur J Cancer 2006;42:1612-22. (Pubitemid 44118763)
3. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004;4:314-22. (Pubitemid 38525287)
4. Teo SK. Properties of thalidomide and its analogues: implications for anticancer therapy. AAPS J 2005;7:E14-9.
5. El Accaoui RN, Shamseddeen WA, Taher AT. Thalidomide and thrombosis. A meta-analysis. Thromb Haemost 2007;97:1031-6.
6. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008;22:414-23. (Pubitemid 351255436)
7. Aird WC. Phenotypic heterogeneity of the endothelium: II. Representative vascular beds. Circ Res 2007;100:174-90.
8. Levi M, Nieuwdorp M, van der Poll T, Stroes E. Metabolic modulation of inflammation-induced activation of coagulation. Semin Thromb Hemost 2008;34:26-32. (Pubitemid 351640879)
9. Key NS, Geng JG, Bach RR. Tissue factor; from Morawitz to microparticles. Trans Am Clin Climatol Assoc 2007;118:165-73.
10. Monroe DM, Key NS. The tissue factor-factor VIIa complex: procoagulant activity, regulation, and multitasking. J Thromb Haemost 2007;5:1097-105. (Pubitemid 46902106)
11. Thompson MA, Witzig TE, Kumar S, Timm MM, Haug J, Fonseca R, et al. Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma. Br J Haematol 2003;123:305-8. (Pubitemid 37305066)
12. Clark PE, Hall MC, Miller A, Ridenhour KP, Stindt D, Lovato JF, et al. Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma. Urology 2004;63:1061-5. (Pubitemid 38746803)
13. Chen N, Lau H, Kong L, Kumar G, Zeldis JB, Knight R, et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol 2007;47:1466-75. (Pubitemid 350115306)
14. Steffel J, Latini RA, Akhmedov A, Zimmermann D, Zimmerling P, Luscher TF, et al. Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design. Circulation 2005;112:2002-11. (Pubitemid 41377420)
15. Fiore MM, Neuenschwander PF, Morrissey JH. An unusual antibody that blocks tissue factor/factor VIIa function by inhibiting cleavage only of macromolecular substrates. Blood 1992;80:3127-34. (Pubitemid 23004517)
16. Fischer EG, Riewald M, Huang HY, Miyagi Y, Kubota Y, Mueller BM, et al. Tumor cell adhesion and migration supported by interaction of a receptor-protease complex with its inhibitor. J Clin Invest 1999;104:1213-21. (Pubitemid 29536292)
17. Ruf W, Rehemtulla A, Edgington TS. Antibody mapping of tissue factor implicates two different exon-encoded regions in function. Biochem J 1991;278(Pt 3):729-33.
18. Bae SK, Seo KA, Jung EJ, Kim HS, Yeo CW, Shon JH, et al. Determination of acetylsalicylic acid and its major metabolite, salicylic acid, in human plasma using liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study of Astrix in Korean healthy volunteers. Biomed Chromatogr 2008;22:590-5. (Pubitemid 351959407)
19. Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med 1984;311:1206-11. (Pubitemid 14021923)
20. Ahamed J, Belting M, Ruf W. Regulation of tissue factor-induced signaling by endogenous and recombinant tissue factor pathway inhibitor 1. Blood 2005;105:2384-91. (Pubitemid 40387035)
21. Kushak RI, Nestoridi E, Lambert J, Selig MK, Ingelfinger JR, Grabowski EF. Detached endothelial cells and microparticles as sources of tissue factor activity. Thromb Res 2005;116:409-19. (Pubitemid 41191193)
22. Arkel YS, Ku DH, Thurston AL. The effect of thalidomide on tissue factor activity in Mono Mac 6 cells and the relationship to tumor necrosis factor (TNF)-alpha-stimulated cells. J Thromb Haemost 2003;1:2691-2.
23. Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007;25:5490-505.
24. Chironi GN, Boulanger CM, Simon A, Dignat-George F, Freyssinet JM, Tedgui A. Endothelial microparticles in diseases. Cell Tissue Res 2009;335:143-51.
25. Vignoli A, Marchetti M, Balducci D, Barbui T, Falanga A. Differential effect of the low-molecular-weight heparin, dalteparin, and unfractionated heparin on microvascular endothelial cell hemostatic properties. Haematologica 2006;91:207-14.
26. Hirsh J, Anand SS, Halperin JL, Fuster V. Guide to anticoagulant therapy: Heparin : a statement for healthcare professionals from the American Heart Association. Circulation 2001;103:2994-3018. (Pubitemid 32578141)
27. Ghosh S, Pendurthi UR, Steinoe A, Esmon CT, Rao LV. Endothelial cell protein C receptor acts as a cellular receptor for factor VIIa on endothelium. J Biol Chem 2007;282:11849-57. (Pubitemid 47100682)
28. Lopez-Sagaseta J, Montes R, Puy C, Diez N, Fukudome K, Hermida J. Binding of factor VIIa to the endothelial cell protein C receptor reduces its coagulant activity. J Thromb Haemost 2007;5:1817-24. (Pubitemid 47288936)
29. Cavo M, Palumbo A, Bringhen S, Falcone A, Pellegrino M, Ciceri F, et al. A phase III study of enoxaparine versus low-dose warfarin versus aspirin as thromboprophylaxis for patients with newly diagnosed multiple myeloma treated up-front with thalidomie containing regimens. Blood 2008;112 abstract 3017.
30. Aue GL, Lozier JL, Cullinane AM, Gibellini F, Tian X, Samsel L, et al. Increased incidence of thrombosis with lenalidomide in chronic lymphocytic leukemia: effect of thalidomide on inflammation, endothelial cell damage and coagulation. Blood (annual meeting abstracts) 2009;114 abstract 455.